Mer­ck can’t prove its Alzheimer’s drug works, yet, but it did just ex­plain why it’s spend­ing a for­tune on PhI­II

In­ves­ti­ga­tors for Mer­ck $MRK have very care­ful­ly out­lined all the ear­ly-stage hu­man and an­i­mal da­ta they can muster for their Alzheimer’s drug verube­ce­s­tat. Now in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.